Scleroderma Foundation Multi-Center Collaborative Grant
A New Scleroderma Foundation Research Funding Initiative
Request for Proposals
Title: Collaborative Scleroderma Research
Purpose: The purpose of this RFP is to solicit applications for collaborative basic, translational or clinical research projects involving two or more Scleroderma Foundation Centers at different institutions. For definition of a Scleroderma Foundation Center, please see the criteria listed at the end of this document*.
Goal: The goal of this RFP is to support and enhance collaborations between two or more Scleroderma Centers to advance significant research on scleroderma. The project must clearly state the proposed impact and significance of the research.
Budget: Applicants may request up to $500,000 for 2 years. A detailed budget is required. No major equipment (> $5,000/year) will be considered. Travel is restricted to one trip per year between Centers. Desktop computers are only considered if used for projects requiring database information and analysis. Indirect costs cannot exceed 8% and are included in the total of $500,000.
Eligible institutions/investigators: Institutions with Scleroderma Foundation Centers are eligible to apply. Non-domestic institutions are not eligible to apply. Investigators conducting Scleroderma research and with the skills necessary to successfully direct and complete the proposed research are eligible as Principal Investigators. Scleroderma Foundation Centers with ongoing or new collaborative efforts are eligible to apply as long as the collaboration project used in response to this RFP is a) new and b) not funded by other sources. The application on behalf of the collaborative centers should be submitted from one primary institution and have a lead principal investigator. Additional principal investigators should be listed as site PI’s only. Administration of funds and submission of financial and progress reports are the responsibility of the applying primary institution.
The project cannot overlap with any currently funded Scleroderma Foundation research grant by any of the investigators.
Number of applications: Primary and site Principal Investigators may not submit more than one multi-center Scleroderma collaborative application in any one funding cycle. However, Principal Investigators may apply for regular Scleroderma Foundation research grants on an unrelated project.
Proposal: Proposals will use the NIH format.
- Each collaborating institution will be required to submit a specific aims page (from the primary Principal Investigator) and a research strategy section limited to 12 pages, including figures/diagrams. In the case of centers that are proposing collaborations with each center conducting independent work, then up to 12 pages/per center is allowed. References have no page limit. Each collaborating institution can submit a portion of the research strategy to indicate the way in which they will be collaborating. All sections should be combined by the submitting institution into a single PDF file.
- The collaborative Centers must submit a plan on how the collaboration will enhance their research efforts and what unique aspect of the collaboration each institution contributes and how the research will benefit patients with scleroderma. Limit: one page.
- All key personnel must submit NIH biosketches, limited to 4 pages that include all current and pending funding.
- Applications that involve human subjects research should include a section on Protection of Human subjects. IRB approval must be obtained prior to grant start date.
- Applications involving animals must include a Vertebrate Animals section. IACUC approval must be obtained prior to the grant start date.
Cores: Cores are allowed; core descriptions should be limited to 3 pages. The need for a core and how it will interact with the individual research projects at the Centers should be clearly described.
Renewal: Successful applicants may submit renewal applications in the final year of the funded Scleroderma Multi-Center Collaboration grant. The renewal should include a detailed progress and financial report that describes progress and productivity of the collaborative Centers for the entire duration of the budget period. Assessment of collaboration success based on publications, success in obtaining subsequent funding from NIH or other sources, and accomplishments will be taken into consideration.
Review: Applications will be reviewed by a peer review panel selected by the Scleroderma Foundation. Applications will be scored using standard review criteria including scientific merit, likelihood of success of the collaboration, and potential for advancing research on scleroderma. Grants in which collaboration can be demonstrated to enhance the overall aims will be given priority.
* Definition of a Scleroderma Foundation Scleroderma Center:
The institution receiving the designation of Scleroderma Foundation Center must:
- Demonstrate expertise in Scleroderma including expertise in clinical and laboratory-based research.
- Conduct clinical trials in Scleroderma.
- Conduct educational activities on Scleroderma and provide information on advances in the care and treatment of patients with Scleroderma to health care professionals and to the public.
- Seek and attain approval as a Scleroderma Center from the Medical Advisory Board of the Scleroderma Foundation. For more information visit http://www.scleroderma.org/site/PageServer?pagename=patients_centers#.UYAufMo5Xh4
Letter of Intent Due Date
September 2, 2013
Application Due Date
October 15, 2013
Scientific Merit Review
Earliest Start Date
January 1, 2014
Letter of Intent
A letter of intent is required prior to application to allow Scleroderma Foundation staff to estimate the potential review workload and plan the review.
Letters of Intent must be received by 5:00 pm EST, September 2, 2013 either via email, mail, or fax. Prospective applicants must submit a letter of intent that includes the following information:
- Descriptive title of proposed research
- Name, address, and telephone number of the Principal Investigators
- Names of other key personnel
- Performance site institutions
- A brief description of proposed research of up to 300 words
The letter of intent should be sent to:
Tracey O’Connell Sperry
National Director of Development and Research
300 Rosewood Drive, Suite 105
Danvers, MA 01923